Lonza Group AG (ETR:LO3)
Germany
· Delayed Price · Currency is EUR 611.20
+12.60 (2.10%)
At close: May 30, 2025
Revenue by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
| Biologics | 3.68B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biologics Growth | 23.81% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Small Molecules | 983.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Small Molecules Growth | 18.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cell & Gene | 689.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cell & Gene Growth | 6.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Capsules & Health Ingredients | 1.05B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Capsules & Health Ingredients Growth | -10.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate | 172.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Growth | 33.77% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
| Biologics Core EBITDA | 1.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biologics Core EBITDA Growth | 16.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Small Molecules Core EBITDA | 351.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Small Molecules Core EBITDA Growth | 38.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cell & Gene Core EBITDA | 108.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cell & Gene Core EBITDA Growth | -20.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Capsules & Health Ingredients Core EBITDA | 256.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Capsules & Health Ingredients Core EBITDA Growth | -29.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Core EBITDA | -73.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Core EBITDA Growth | 26.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
| Europe | 3.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North and Central America | 2.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North and Central America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America | 129.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia | 837.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Australia & New Zealand | 17.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Australia & New Zealand Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographic | 3.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographic Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|